The interaction of factor Vlll with von Willebrand factor (vWF) was investigated on a quantitative and qualitative level. Binding characteristics were determined using a solidphase binding assay and protection of factor Vlll by vWF from inactivation by activated protein C (aPC) was studied using three different assays. Deletion mutants of vWF, a 31-kD N-terminal monomeric tryptic fragment of vWF that contained the factor Vlll binding site (T31) and multimers of vWF of different size were compared with vWF purified from plasma. We found that deletion of the AI, A2, or A3 domain of vWF had neither an effect on the binding characteristics nor on the protective effect of vWF on factor VIII. Furthermore, no differences in binding of factor Vlll were found between multimers of vWF with different size. Also, the protective effect on factor Vlll of vWF was not related to the size of the multimers of vWF. A 20-fold lower binding affinity was observed for the interaction of T31 with factor VIII, and T31 did not protect factor Vlll from inactivation by aPC in a fluid-phase assay. Comparable results were found for a mutant of vWF that is monomeric at the N-terminus (vWFdPRO). The lack of multimerization at the N-terminus may explain the decreased affinity of T31 and vWF-dPRO for fac-ACTOR VI11 IS THE procofactor for factor IXa in the activation of factor X.' The in vivo importance of factor VI11 is shown by the bleeding tendency in hemophilia A caused by a deficiency of factor VI11 (reviewed by Rizza'). Factor VI11 circulates in plasma in complex with von Willebrand factor (vWF), a large multimeric protein involved in the adhesion of platelets to the damaged vessel wall.' Each subunit of vWF consists of a repetition of four distinct domains. The sequence of the precursor form of vWF is generally expressed as NH2-D1-D2-D'-D3-A 1 -A2-A3-D4-Bl-B2-B3-Cl-C2-COOH, in which the D l and D2 domains represent the propeptide (Fig 1A) . Multimerization takes place in two consecutive steps. First, C-terminal dimers are formed in the rough endoplasmatic reticulum via disulphidebridge formation at the C l domain. Second, dimers form Nterminal multimers at their D3 domain in the Golgi apparatus (reviewed by Wagner4). After formation of the disulphide bonds, the propeptide is cleaved off. Both the mature vWF The publication costs of this article were defrayed in part by page charge payment. This article must therefore be herebv marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.
The interaction of factor Vlll with von Willebrand factor (vWF) was investigated on a quantitative and qualitative level. Binding characteristics were determined using a solidphase binding assay and protection of factor Vlll by vWF from inactivation by activated protein C (aPC) was studied using three different assays. Deletion mutants of vWF, a 31-kD N-terminal monomeric tryptic fragment of vWF that contained the factor Vlll binding site (T31) and multimers of vWF of different size were compared with vWF purified from plasma. We found that deletion of the AI, A2, or A3 domain of vWF had neither an effect on the binding characteristics nor on the protective effect of vWF on factor VIII. Furthermore, no differences in binding of factor Vlll were found between multimers of vWF with different size. Also, the protective effect on factor Vlll of vWF was not related to the size of the multimers of vWF. A 20-fold lower binding affinity was observed for the interaction of T31 with factor VIII, and T31 did not protect factor Vlll from inactivation by aPC in a fluid-phase assay. Comparable results were found for a mutant of vWF that is monomeric at the N-terminus (vWFdPRO). The lack of multimerization at the N-terminus may explain the decreased affinity of T31 and vWF-dPRO for fac-ACTOR VI11 IS THE procofactor for factor IXa in the activation of factor X. ' The in vivo importance of factor VI11 is shown by the bleeding tendency in hemophilia A caused by a deficiency of factor VI11 (reviewed by Rizza'). Factor VI11 circulates in plasma in complex with von Willebrand factor (vWF), a large multimeric protein involved in the adhesion of platelets to the damaged vessel wall.' Each subunit of vWF consists of a repetition of four distinct domains. The sequence of the precursor form of vWF is generally expressed as NH2-D1-D2-D'-D3-A 1 -A2-A3-D4-Bl-B2-B3-Cl-C2-COOH, in which the D l and D2 domains represent the propeptide (Fig 1A) . Multimerization takes place in two consecutive steps. First, C-terminal dimers are formed in the rough endoplasmatic reticulum via disulphidebridge formation at the C l domain. Second, dimers form Nterminal multimers at their D3 domain in the Golgi apparatus (reviewed by Wagner4). After formation of the disulphide bonds, the propeptide is cleaved off. Both the mature vWF tor VIII. Because of this decreased affinity, only a small fraction of factor Vlll was bound t o T31 and t o vWF-dPRO. We hypothesized that this fraction was protected from inactivation by aPC but that this protection was not observed due to the presence of an excess of unbound factor Vlll in the fluid phase. Therefore, vWF, T31, and vWF-dPRO were immobilized t o separate bound factor Vlll from unbound factor Vlll in the fluid phase. Subsequently, the protective effect of these forms of vWF on bound factor Vlll was studied. In this approach, all forms of vWF were able t o protect factor Vlll against inactivation by aPC completely. We conclude, in contrast with earlier work, that there is no discrepancy between binding of factor Vlll t o vWF and protection of factor Vlll by vWF from inactivation by aPC. The protective effect of T31 was not recognized in previous studies due to its low affinity for factor VIII. The absence of multimeriration observed for T31 and vWF-dPRO may explain the low affinity for factor VIII. No other domains than the binding site located at the D' domain were found t o be involved in the protection of factor Vlll from inactivation by aPC.
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and its propeptide, also known as vWF antigen 11, are secreted in plasma. Approximately 1 % of the circulating vWF contains the pr~peptide,~ possibly due to incorrect processing. The propeptide of vWF plays an important role in the posttranslational modification of vWF. A mutant of vWF that lacked the propeptide (VWF-dPROj did not multimerize at the N-terminus, but was dimeric at the C-terminus.' The role of the propeptide of vWF in the formation of the factor VI11 binding site is unclear. Leyte et al' described that vWFdPRO did not bind factor VIII, whereas one of us reported that vWF-dPRO was able to bind and stabilize recombinant factor VI11 upon secretion by C H 0 c e k x Binding of factor VI11 to vWF is required for optimal survival of factor VI11 in vivo."~'* The binding site for factor VI11 is located in the first 272 amino acids of the vWF subunit.'% More precisely, the first 106 amino acids were identified as the factor VI11 binding site.I4 A monoclonal antibody (MoAbj directed against a peptide representing amino acids 78-96 inhibited the binding of factor VI11 to vWF." The presence of a primary factor VI11 binding site on the N-terminal region of vWF is underscored by a recently described variant of von Willebrand disease, type Normandy. Point mutations at amino acids 28, 53, or 91 lead to a defective factor VI11 binding, resulting in a hemophilia A-like bleeding disorder (reviewed by Mazurier").
Interestingly, not every subunit of the vWF multimer participates in the binding of factor VI11 in vivo. The plasma concentration of factor VIII is approximately I nmol/L," and, although the concentration of vWF is not commonly expressed in molars because of the varying length of the multimers, it is approximately 50 n m o n in monomer^.'^ This ratio of factor VI11 to vWF remains unchanged when the concentration vWF is altered. This is shown by a decreased level of factor VIII in severe von Willebrand dis- ease," whereas factor VI11 is elevated during episodes of increased vWF concentrations as in the acute-phase reaction." However, in vitro, ratios of factor VI11 to vWF of 1 to 1 on a molar base are observed." Factor VI11 is proteolytically degraded by activated protein C (aPC).2"23 Cofactors in this reaction are phospholipid surface, calcium ions, and protein S.24-28 Shen and Dahlback" proposed that factor V can also act as a cofactor for aPC in the presence of protein S. In an earlier study, we showed that vWF can protect factor VI11 against &-mediated degradati~n.~' The underlying mechanism may be that factor VI11 bound to vWF does not interact with phospholipid surfaces" or activated platelets3' and that factor VI11 therefore is a poor substrate for aPC." 
VWF-dAl vWF-dA2 vWF-dA3
To obtain optimal protection, a ratio factor VI11 to vWF of 1 to 1 in units ( l to 50 on a molar base) was req~ired.~' This may explain the in vivo ratio of factor VI11 and vWF.
It is generally accepted that the factor VI11 binding site is located on the first 272 amino acids of vWF, but, strikingly,' a fragment representing this binding site was not sufficient to protect factor VI11 against aPC-mediated degradathat contained the D', D3, A l , A2, and part of the A3 domain did protect factor VI11 against inactivation by aPC" (Fig  1A) . The difference in protection against inactivation by aPC between these two fragments may be explained by the presence of the D3, A l , A2, and A3 domain in the 120- This study was performed to elucidate the mechanism by which vWF protects factor VI11 against inactivation by aPC.
Using a tryptic fragment and several mutants of vWF ( Fig  1B) we found, in contrast with earlier work, that binding of factor VI11 to the small tryptic fragment representing the first 272 amino acids of vWF is sufficient to protect factor VI11 against aPC-catalyzed degradation.
MATERIALS AND METHODS

Materials.
Purified recombinant factor VI11 was a generous gift from Dr D. Pittrnan (Genetics Institute, Cambridge, MA). Factor VI11 concentrations are commonly expressed in units per mL. One unit represents the amount of factor VI11 activity in 1 mL of pooled normal human plasma. Assuming a molecular weight of 250 kD and a plasma concentration of 0.2 pg/mL, 1 U/mL corresponds to 1 nmol/L. Factor VI11 concentrates used for the purification of vWF were from the Red Cross Blood Bank (Friesland, The Netherlands) and were, for this purpose, not heat-treated. Protein-G Sepharose was obtained from Pharmacia (Uppsala, Sweden). The factor VI11 Coatest and chromogenic substrate S2366 were obtained from Chromogenix (Stockholm, Sweden). Ninety-six-well plates were from Costar (Cambridge, MA). Bovine serum albumin (BSA) and bovine brain cephalin were purchased from Sigma (St Louis, MO). Bio-Gel A15 was from BioRad (Richmond, CA). All other chemicals were of the highest grade available.
Antibodies. MoAb CLB-CAgA directed against the light chain of factor VI11 and MoAb CLB-41 directed against the C-terminus of vWF were kind gifts of Dr J.A. van Mourik (Central Laboratory of The Netherlands Red Cross Blood Transfusion Services, Amsterdam, The Netherlands). An enzyme-linked immunosorbent assay (ELISA) to measure vWF was constructed using polyclonal antibodies (PoAbs) and peroxidase-conjugated PoAbs directed against vWF (DAKO, Glostrup, Denmark) with normal pooled plasma used as a standard. T31 was measured using the same ELISA, with purified T31 as a standard.
Construction of mutants of vWF. vWF that was dimeric at the C-terminus (VWF-dPRO) was described earlier." The polymerase chain reaction (PCR) gene fusion technique36 was used to construct the other deletion mutants of vWF. Amino acids 478 to 716, 730 to 910, or 910 to 11 13 were deleted to obtain vWF lacking the A1 domain (vWF-dAl), the A2 domain (vWF-dA2), or the A3 domain (vWF-dA3), respectively. Deletion constructs were cloned in the pNUT-expression vector." Because furin cleaves off the propeptide of vWF, which is necessary in the formation of vWF mulitmers, furin cDNA containing baby hamster kidney cells were used for transfection. Stable cell lines were selected with methotrexate. Recombinant vWF was expressed in medium containing 1% Ultroser G and was purified using immunoaffinity chromatography techniques.
Purijcation ofproteins. vWF devoid of factor VI11 was prepared by gel filtration of factor VI11 concentrates on a Biorad A-l5 column (100 X 1.6 cm) in 50 mmol/L Tris, pH 7.4, containing 150 mmoV L NaCl and 0.25 mom CaCI2. Fractions of 10 mL were collected and tested for vWF antigen and factor VI11 antigen. Multimer analysis was performed as described." The factor VIII-free, vWF-containing fractions were dialyzed against 50 mmollL N-2-hydroxyethylpiperazine-N'-2ethane sulfonic acid (HEPES), pH 7.4, containing 150 mmol/L NaC1. Reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed one band at 240 kD and a faint triplet at 40-48-60 kD (probably representing fibrinogen, approximately 1 % of the total amount of protein). T3 1 was prepared from purified vWF as de~cribed"~ and showed on a nonreduced SDS-PAGE a doublet at 31 kD. Protein C was purified and activated as described previously.3o aPC showed on SDS-PAGE a doublet at approximately 60 k D . Protein concentrations were measured with the BCA protein assay (Pierce, Rockford, IL) according to the manufacturer's instructions with BSA as a standard. Factor VIII-vWF binding assay. Microtiter wells were coated overnight with 1 pg/mL MoAb CLB-41 directed against vWF in 50 mmolL Na2C03, pH 9.6 at 4°C. The wells were washed once with 50 rnmol/L Tris, pH 7.4, 150 rnmol/L NaCI (TBS) containing 0.1 % Tween-20. After blocking with TBS containing 0.1% Tween-20 and 3% BSA for 1 hour at 3 7 T , the wells were incubated with different forms of vWF (0.25 n m o E [0.005 UlmL]) in TBS containing 0.1% Tween-20 and 3% BSA for 2 hours at 37°C. The concentrations of vWF before and after incubation were measured with a vWF ELISA. By subtracting both concentrations and taking into account the volume of the wells, the amount of vWF bound to the wells was calculated. The wells were washed three times with TBS containing 0.2% Tween-20 and subsequently incubated with factor VI11 (0 to 20 nmoUL) in TBS containing 0.1 %Tween-20, 3% BSA, and 3 mmollL CaC1, for 1 hour at 37°C. After washing three times with TBS containing 0.1% Tween-20, bound factor VI11 was quantified using the factor VI11 Coatest (Chromogenix) with purified factor VI11 as reference. When normal plasma was used as a source of vWF, a U200 dilution of plasma in TBS containing 0.1% Tween-20 and 3% BSA was used instead of purified vWF. After washing, endogenous factor VI11 was removed by incubation with TBS containing 0.1% Tween-20, 3% BSA, and 250 mmol/L CaClz for 30 minutes at 37°C. In another series of experiments, purified vWF or T31 was coated directly to the wells in 50 mmol/L NazCO,, pH 9.6, overnight at 4°C. Nonspecific binding of factor VI11 to the wells was determined in the absence of vWF and was less than 10%. Dissociation constants and stoichiometries were calculated by Scatchard analysis of the data using Enzfitter software."' Inactivation of factor VIII by aPC in solution. Factor VI11 ( I . I nmoVL [1.1 UlmL]) was incubated with vWF (0 to 165 nmol/L [0 to 3.3 U/mL]) for 30 minutes at 37°C in 100 pL of 50 mmol/L HEPES, pH 7.4, containing 0.3% BSA, 150 mmoUL NaCI, and 3 mmol/L CaCIz. After the addition of I O pL of a 1/10 dilution of cephalin and incubation for 30 minutes, the reaction was started by the addition of aPC (4 nmol/L final concentration). Samples of 5 pL were collected and immediately diluted 100-fold in ice-cold TBS containing 0.3% BSA and 5 nmol/L (0.1 U/mL) vWF to prevent further inactivation of factor VI11 by aPC. Once diluted, factor VI11 was stable for at least 1 hour. Factor VI11 was measured using the factor VU1 Coatest. Control experiments using the chromogenic substrate S2366 showed that neither form of vWF inhibited aPC directly.
Inactivation of factor VIII bound to vWF immobilized on microtiterplates. Wells were coated with vWF (0.5 nmol/L 10.1 pg/mLI),
rnmoVL Na,CO,, pH 9.6, at 4°C. Wells were washed three times with TBS containing 0.1% Tween-20. After blocking with TBS containing 0.1% Tween-20 and 3% BSA for 1 hour at 37°C factor VI11 (25 nmol/L [25 U/mL]) was incubated for 1 hour at 37°C in TBS containing 0.1% Tween-20, 3% BSA, and 3 mmol/L CaCI2. The wells were washed three times with TBS containing 0.1% Tween, and bound factor VI11 was incubated with 0 to 4 nmol/L aPC for 5 minutes. Microtiter plates were emptied and the remaining factor VI11 was measured using the factor VI11 Coatest. Nonspecific binding of factor VI11 to the wells was determined in the absence of vWF and was less than 10%. was added. After mixing for 30 minutes, samples were layered on 1 mL of 20% (wt/wt) sucrose in TBS containing 0.3% BSA, 0.1% Tween-20, and 3 mmoVL CaC1,. After centrifugation for 3 minutes at 3,000 rpm, the Sepharose pellet containing bound factor VIII was resuspended, diluted to 50 pmom (0.05 U/mL) of factor VIII, and immediately treated with 100 pmoVL aPC for 5 minutes at 37°C. Incubation mixtures were diluted 5 times in TBS containing 3% BSA and immediately assayed for factor VIII activity using the factor VIII Coatest. Factor VIII in complex with MoAb CLB-CAgA, which does not protect against aPC, was bound to protein G Sepharose and treated the same way to show that the activity of aPC was not altered by the presence of Sepharose. Nonspecific binding of factor VI11 to Sepharose was determined using protein G Sepharose in the absence of anti-vWF PoAbs (< 15% of the total amount of factor VIII).
RESULTS
The binding of factor VIII to the difSerent forms of vWF. The stoichiometry and binding affinity of the interaction of factor VI11 with v W F was studied using a solid-phase binding assay. Various amounts of purified factor VIII were incubated for 1 hour on immobilized v W F and bound factor VI11 was measured using a chromogenic assay. This solid-phase binding assay was previously used to study the interaction between factor VI11 and vWF.20s34*41 Figure 2 shows the saturation curve of the binding of factor VI11 to v W F purified from plasma. Scatchard analysis of the data showed a single class of high-affinity binding sites with a dissociation constant of 0.3 +-0.03 nmoVL. The stoichiometry at saturation was l mol of factor VIII per 50 mol of v W F (1 .O U factor VIII per 1.0 U vWF). The characteristics of the binding between factor VIII and the different forms of vWF were tested using this binding assay. Table 1 shows the dissociation constants and stoichiometries at saturation. vWF captured directly from plasma yielded the same binding characteristics as purified vWF, indicating that the purification fragment consists of the first 272 amino acids of vWF. We found that the binding affinity of this fragment was 20-fold lower as compared with the intact vWF molecule. Also, the stoichiometry of the binding was 50-fold lower (Table 1) . Although no binding affinities of fragments like T31 for factor VIII were published, the stoichiometry that we have found is comparable with the stoichiometry described by Layet et To investigate whether other N-terminal domains of vWF contributed to the factor VI11 binding, mutants of vWF lacking the Al, A2, or A3 domain were tested on factor VI11 binding. These recombinant vWF molecules had the same binding properties as vWF purified from plasma (Table l) . vWF-dPRO had a 10-fold lower affinity for factor VIII compared with the mature molecule, whereas the stoichiometry of the binding was not different ( Table 1 ). The multimeric composition of vWF-dA2 and vWF-dA3 was similar to that of vWF in normal plasma, whereas vWF-dAl consisted of primarily intermediate and small multimers (data not shown). The vWF-dPR0 preparation consisted primairily of dimeric v W F .~~ Protection of factor VIII from inactivation by aPC by different forms of vWF in a fluid-phase assay. Factor VI11 (1 nmol/L, 1 U/&) was treated with 4 nmol/L aPC in the presence of an optimal concentration of cephalin. Figure 3 shows a time course of the inactivation of factor VI11 by aPC. Factor VI11 activity decreased with a half-life of approximately 8 minutes, whereas vWF (50 nmol/L [l U/mLI) KOPPELMAN ET AL completely protected factor VI11 from inactivation by aPC (Fig 3) . Because factor VI11 in the absence of vWF is a labile molecule, we followed the factor VI11 activity in the absence of both vWF and aPC. During the time course of the experiment, no significant decrease of factor VI11 activity was observed. To investigate the protective effect of vWF in more detail, several concentrations of vWF were used. Figure 4 shows the protection of factor VI11 by vWF against aPC-mediated proteolytical degradation. A concentration of l nmol/L (1 U/mL) factor VI11 is optimally protected by 50 nmol/L (1 U/mL) of vWF, whereas lower concentrations of vWF only partially protected factor VI11 from inactivation by aPC. As a measure for the protection against aPC, the concentration of vWF necessary for half-maximal protection was determined. For vWF purified from plasma, this concentration was 6 ? 1 nmol/L (0.12 -C 0.02 U/mL; Fig 4) . T3 1 did not protect factor VI11 against aPC (Fig 4) . Based on the affinity of T3 1 for factor VIII, one might expect that T31 should provide some protection, but, due to the low stoichiometry of this interaction, no protection of T3 1 against aPC was found. The different mutants of vWF were also tested for their ability to protect factor VI11 against aPC. Table 2 shows the concentrations of the different forms of vWF at which half-maximal protection against aPC was reached. No protection by T3 1 and vWF-dPRO could be shown, whereas the deletion of the AI, A2, or A3 domain did not affect the protective effect. There was no difference in protection found between the high, intermediate, and low multimers (Table   100   75 For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From A concentration of 1 nmol/L (1 U/mL) of factor Vlll was incubated with 0 to 100 nmol/L (0 to 2 U/mL) of vWF for 2 hours. aPC at 4 nmol/L was added and the remaining activity after 15 minutes was measured. Saturation plots as depicted in Flg 4 were fit and the concentration of vWF necessary for half-maximal protection against aPC was determined.
Protection of factor VI11 against proteolytic degradation is closely related to the binding to vWF in vivo and in vitro. As described above, T31 and vWF-dPRO have decreased affinities for factor VIII as compared with the mature molecule (Table l) . Also, they did not protect factor VI11 against aPC ( Table 2) . Because of the decreased affinity of vWFdPRO and T31 for factor VI11 and the low stoichiometry of the interaction between factor VI11 and T31, only a small fraction of factor VIII may be bound to these forms of vWF. We hypothesized that this fraction was protected against aPC, but that this protective effect was not observed, due to the presence of an excess of unbound factor VIII. Therefore, we developed an assay that allowed us to investigate the inactivation of factor VI11 bound to T31 or to vWF-dPRO in the absence of free factor VIII. The different forms of vWF were coated on microtiter plates and incubated with factor VIII. The coat concentrations were chosen such that the amount of bound factor VI11 was the same for all forms of vWF and that the amount of factor VI11 was the same as in the solid-phase binding assay. All forms of vWF protected factor VI11 from inactivation by aPC completely (Fig 5) , indicating that T3 1 and vWF-dPRO protected factor VI11 as well as mature vWF. The possibility that aPC was not able to inactivate factor VI11 in this assay was excluded because factor VIII bound to the microtiter plate via an MoAb directed against its light chain was degraded by 70%. Because binding of factor VI11 to vWF immobilized on a microtiter plate was shown to be different from binding of factor VI11 to vWF in solution," we also used a fluid-phase assay to separate factor VI11 bound to vWF from free factor VIII. Factor VI11 was incubated with the T31, vWF-dPRO, or mature vWF. Bound factor VI11 was then isolated by incubation with Sepharose-linked polyclonal antibodies against vWF and subsequent centrifugation through a sucrose layer. The pellet was immediately resuspended, diluted to 50 pmoV L, and then treated with aPC and assayed for remaining factor VI11 activity. Dilution to 50 pmol/L does not induce dissociation of the complex within the experimentation time (data not shown). Figure 5 shows that all forms of vWF protected factor VI11 equally well. Factor VI11 bound to Sepharose via an MoAb directed against the factor VI11 light chain (CLB-CAgA) was not protected against aPC in this assay. The results of the experiments with isolated bound factor VI11 indicate that binding of factor VI11 to T31 or to vWF-dPRO is sufficient for protecti on against aPC.
DISCUSSION
Survival of factor VIII in vivo strongly depends on complex formation with v W F .~"~ Free factor VI11 is rapidly cleared from the circulation, whereas factor VI11 in complex with vWF decays with the half-life of vWF. Earlier work showed that vWF protects factor VI11 against inactivation by aPC. 30 The inactivation of factor VI11 by aPC is a phospholipid-dependent process and, because the binding sites for both phospholipid and vWF on factor VI11 are located in close spatial proximity on the light chain, masking of the phospholipid binding site on factor VI11 by vWF may explain the protective effect of v W F .~' The binding site for factor VI11 is located on the first 272 amino acids of vWF,*' but N-terminal fragments (amino acids 1-272, T3133 and SPIII-T43' or 1-298, P34") containing this binding site are not sufficient to protect factor VI11 against inactivation by aPC in the fluid phase. The smallest fragment of vWF that is able to both bind and protect factor VI11 is a 120-kD N-terminal fragment. 34 The difference between the 1 2 0 4 3 and T31 or P34 is not only the presence of the D3, Al, A2, and a part of the A3 domain, but also that the 120-kD fragment is dimeric at the N-terminus. Therefore, the discrepancy in binding and protection of factor VI11 may be explained in two ways. First, the D3, Al, A2, or A3 domain may play an important role in the protection of factor VIII. Second, dimerization may be required for optimal protection. To elucidate the mechanism of protection of factor VI11 from aPCmediated inactivation, we tested several forms of vWF on their ability to bind factor VI11 and to protect it against inactivation by aPC.
Using a solid-phase binding assay, we found that factor VI11 bound to vWF with a kd of 0.30 nmoVL, corresponding to previously described v a l~e s .~~.~' Although solid-phase binding assay may not represent true equilibrium binding, we found in a previous study the same binding affinities using a fluid-phase binding assay." More recent work showed that the kd found using the fluid-phase binding assay represented indeed the ratio of hiss and kassr43 indicating that our solid-phase binding assay is suitable to determine binding affinities. Comparing multimers of vWF of different size, we found the same affinities for factor VI11 for the different multimers. Deletion of the Al, A2, or A3 domain did not alter the binding characteristics, but deletion of the pro-peptide of vWF resulted in a 10-fold lower affinity. The propeptide of vWF is required for the multimerization of the vWF subunits at the N -t e r m i n u~,~~.~ and deletion of this pro-peptide resulted in the expression of vWF, which was dimerized at the C-terminus (VWF-dPRO) while the N-termi- nus was not multimerized." The ability of vWF-dPRO to bind factor VIII is disputed. One of us reported that the factor VIII binding is unaltered: whereas Leyte et a17 reported defective factor VI11 binding by vWF-dPRO. This difference is most likely explained by the different cell types used for the expression of both forms of vWF-dPRO or by the presence of an extra Ala residue in vWF-dPRO described by Leyte et al. ' We used vWF-dPRO described by Wise et a135 and found that it was able to bind factor VIII, although with a 10 times lower affinity than normal vWF, either purified from plasma or full-length recombinant vWF. The Nterminal fragment T3 1 that contained the factor VI11 binding site had also a lower affinity for factor VI11 as compared with normal vWF. Binding of factor VI11 to fragments similar to T31 was described earlier, but the affinity of the interaction was not r e p~r t e d . l~.~' ,~~*~~ The stoichiometry that we have found the interaction between factor VIII and T3 1 is comparable with the stoichiometry described by Layet et al. 34 They found that this stoichiometry was decreased 20-to 50-fold as compared with mature vWF. This decrease in stoichimetry was explained by significant conformatial changes due to proteolytical degradati~n.~~ Because a 120-kD N-terminal fragment both binds and protects factor VIII quite as well as normal v W F , the low affinity that we have found for the interaction of T31 with factor VIII may be explained in two ways. First, other domains of vWF may be required for optimal binding of factor VIII. However, this is not likely because deletion of the Al, A2, or A3 domain did not influence the binding of factor VIII. Deletion of the D3 domain was not possible because this domain contains the cysteine residues involved in the disulphide bond formation required for the multimerization. Because vWF-dPRO, which contains all domains of the mature vWF, also expressed a low affinity for factor VIII, a possible role for the D3 domain in the binding of factor VI11 is unlikely. The other explanation for the decreased binding affinity may be that the multimerization at the N-terminus of the vWF subunits is important for the factor VIII binding. This is in agreement with the binding characteristics of vWFdPRO, which is also not multimerized at the N-terminus. Based on these results, we suggest that dimerization at the N-terminus of the vWF subunits increases the binding affinity for factor VIII. However, this dimerization is not a requirement to bind factor VIII. We found that vWF was able to protect factor VIII against aPC in the fluid phase. As a standard for protection of factor For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From VI11 by vWF, we measured the concentration of vWF necessary for half-maximal protection. Because factor VI11 binds to both phospholipid surfaces and vWF, the presence of phospolipid decreases the binding affinity of vWF for factor VIIJ?5.46 Therefore, values found for half-maximal protection can not be compared with the binding affinity as presented in Talbe 1. Deletion of either the Al, A2, or the A3 domain did not affect the protective effect of vWF. No differences in protection were found between multimers of vWF of different size. However, vWF that was dimeric at the C-terminus and that expressed a monomeric N-terminus (VWF-dPRO), did not protect factor VI11 against inactivation by aPC. The same results were obtained for T31, which is also monomeric at the N-terminus. Based on the kd for the interaction between T31 and factor VIII of 5.2 nmol/L described in this study, one might expect that 100 nmol/L T31 should protect 1 nmolL factor VI11 to some extent. However, this was not observed (Fig 4) . Because of the low stoichiometry of the binding of factor VI11 to T31, protection of factor VI11 by T31 is expected at a molar excess of T31 of at least 2,500. T31 and vWF-dPRO have low affinity for factor VI11 as compared with normal vWF and the interaction of factor VI11 with T3 1 expressed a low stoichiometry. These parameters predict that, in a mixture of factor VI11 and T31 or vWF-dPRO, only a small fraction of factor VI11 is bound to T3 1 or vWF-dPRO. The presence of an excess of unbound factor VIII, which is not protected against inactivation by aPC, may mask a possible protective effect on the bound fraction of factor VIII. These considerations devaluate the assay that we and others have used to investigate a possible protective effect of vWF fragments on factor VIII. Therefore, two assays were developed in which factor VI11 bound to the different forms of vWF was separated from free factor VIII. In the first assay, factor VI11 was bound to the different forms of vWF coated on microtiter plates. Factor VI11 bound to all forms of vWF used in this study appeared to be completely protected against aPC. The binding of factor VI11 to vWF immobilized on a surface is different from the binding in solution.'' Although the same affinity is found in both systems, the stoichiometry of the binding in the fluid-phase is 20-fold higher." The underlying mechanism for the discrepancy of factor VI11 binding in the solid-and fluid-phase assay is not entirely understood. To exclude possible effects of the immobilization of the different forms of vWF, a fluidphase assay was developed in which bound factor VI11 was separated from unbound factor VIII. In this assay, factor VI11 bound to the different forms of vWF was isolated by incubation with antibodies against vWF bound to Sepharose beads and subsequent centrifugation through a sucrose layer. This assay expresses fluid-phase binding characteristics because vWF is immobilized to a less rigid Using this fluid-phase assay, we found that factor VI11 bound to any form of vWF was completely protected against aPC.
We conclude, in contrast with earlier work, that factor VI11 bound to the 31-kD monomeric N-terminal fragment of vWF is protected against degradation by aPC. Because of the low affinity of this fragment for factor VIII, this protective effect cannot be observed in fluid-phase assays. The low binding affinity of this fragment for factor VI11 may be explained by the monomeric state of its N-terminus. We suggest that the multimerization of vWF at the N-terminus is necessary for the expression of a high-affinity binding site for factor VIII, whereas the degree of multimerization does not affect the binding of factor VIII.
